Your browser is no longer supported. Please, upgrade your browser.
Settings
DXCM DexCom, Inc. daily Stock Chart
DXCM [NASD]
DexCom, Inc.
Index- P/E- EPS (ttm)-0.77 Insider Own1.70% Shs Outstand88.06M Perf Week-4.77%
Market Cap3.96B Forward P/E- EPS next Y-0.37 Insider Trans-6.13% Shs Float85.16M Perf Month-35.29%
Income-65.00M PEG- EPS next Q-0.16 Inst Own- Short Float14.40% Perf Quarter-35.79%
Sales632.70M P/S6.26 EPS this Y-8.70% Inst Trans0.28% Short Ratio6.13 Perf Half Y-40.78%
Book/sh4.09 P/B10.99 EPS next Y53.80% ROA-12.80% Target Price71.99 Perf Year-45.53%
Cash/sh5.64 P/C7.97 EPS next 5Y35.00% ROE-22.10% 52W Range42.62 - 88.80 Perf YTD-24.71%
Dividend- P/FCF- EPS past 5Y-2.80% ROI-22.80% 52W High-49.38% Beta0.22
Dividend %- Quick Ratio5.80 Sales past 5Y49.70% Gross Margin67.90% 52W Low5.47% ATR2.22
Employees1900 Current Ratio6.20 Sales Q/Q24.30% Oper. Margin-12.40% RSI (14)22.81 Volatility2.85% 3.58%
OptionableYes Debt/Eq0.00 EPS Q/Q113.90% Profit Margin-10.30% Rel Volume0.66 Prev Close44.99
ShortableYes LT Debt/Eq0.93 EarningsNov 01 AMC Payout- Avg Volume2.00M Price44.95
Recom1.80 SMA20-16.19% SMA50-31.12% SMA200-38.05% Volume1,322,915 Change-0.09%
Sep-28-17Reiterated Wedbush Outperform $85 → $76
Sep-28-17Downgrade Raymond James Outperform → Mkt Perform
Sep-28-17Downgrade Northland Capital Outperform → Market Perform
Sep-28-17Downgrade JP Morgan Overweight → Neutral
Sep-26-17Initiated Northland Capital Outperform $85
Sep-15-17Initiated Barclays Equal Weight $76
May-22-17Resumed Piper Jaffray Overweight
May-03-17Reiterated Canaccord Genuity Buy $95 → $90
Jan-03-17Downgrade Morgan Stanley Overweight → Equal-Weight $66
Dec-19-16Upgrade Oppenheimer Perform → Outperform
Nov-02-16Reiterated Canaccord Genuity Buy $100 → $70
Aug-03-16Reiterated The Benchmark Company Buy $86 → $106
Feb-24-16Reiterated The Benchmark Company Buy $105 → $86
Feb-08-16Downgrade Robert W. Baird Outperform → Neutral $100 → $74
Nov-02-15Initiated Morgan Stanley Overweight
Oct-15-15Upgrade Sterne Agee CRT Neutral → Buy
Oct-15-15Upgrade Leerink Partners Mkt Perform → Outperform
Sep-17-15Reiterated JP Morgan Overweight $95 → $120
Aug-06-15Reiterated Canaccord Genuity Buy $69 → $95
Jul-08-15Initiated Robert W. Baird Outperform $95
Oct-17-17 09:40AM  ETFs with exposure to DexCom, Inc. : October 17, 2017 Capital Cube
Oct-10-17 04:30PM  DexCom Schedules Third Quarter 2017 Earnings Release and Conference Call for November 1, 2017 at 4:30 p.m. Eastern Time Business Wire
Oct-09-17 01:26PM  DexCom's Quiet Consolidation After Huge Decline Benzinga
Oct-06-17 10:46AM  ETFs with exposure to DexCom, Inc. : October 6, 2017 Capital Cube
Oct-05-17 09:36AM  DexCom, Inc. :DXCM-US: Earnings Analysis: Q2, 2017 By the Numbers : October 5, 2017 Capital Cube
Oct-04-17 08:45PM  5 Top Stocks for October Motley Fool
07:19PM  Cramer Remix: My mea culpa on DexCom and where its heade... CNBC Videos
07:00PM  Cramer Remix: My mea culpa on DexCom and where its headed CNBC
Oct-03-17 07:43AM  How Wall Street Reacted to the FDA Approval of Abbotts Freestyle Libre Market Realist
Sep-29-17 08:20AM  Today's Research Reports on Stocks to Watch: Abbott Laboratories and DexCom ACCESSWIRE +7.67%
Sep-28-17 05:00PM  What Happened in the Stock Market Today Motley Fool -32.65%
04:45PM  DexCom and Rite Aid tumble while Abbott and AbbVie rise Associated Press
04:04PM  Rite Aid, DexCom Plunge into Thursdays 52-Week Low Club 24/7 Wall St.
03:42PM  The FDA just approved a device that can monitor blood sugar without finger pricks Business Insider
01:17PM  Buy Abbott Labs as It Obliterates DexCom Stock, Jim Cramer Says TheStreet.com
12:58PM  Canaccord Sticks With Dexcom As Shares Tumble Amid Unexpected Label Addition Benzinga
11:53AM  Why DexCom Stock Is Getting Crushed Today Motley Fool
11:48AM  Abbott shares jump after approval for diabetes monitor; competitor DexCom crashes on surprise news CNBC
11:00AM  DexCom: Stay Sweet or Go Sour? Barrons.com
10:59AM  Fitbit Stock Briefly Touches New Highs Investopedia
Sep-27-17 06:40PM  FDA approves Abbott's blood glucose monitoring device Reuters
06:28PM  FDA Approves First Finger Prick-Free Device for Diabetics Bloomberg
05:54PM  FDA approves Abbott's blood glucose monitoring device Reuters
Sep-26-17 07:18AM  Fitbit Inc (FIT) Stock Looks Good for the Very Short Term InvestorPlace
Sep-22-17 08:02AM  See what the IHS Markit Score report has to say about Dexcom Inc. Markit
Sep-20-17 01:06PM  Fitbit Stock Tests Support After Breakout Fizzles Investopedia
Sep-19-17 09:14AM  Fitbit Inc (NYSE:FIT) Stock Still Has A Lot of Work To Do InvestorPlace
08:00AM  DexCom Opens Data Platform and Launches Developer Program to Fuel Diabetes App Innovation Business Wire
Sep-12-17 01:14PM  Why Fitbit Inc (FIT) Stock Is Rising on the Latest Ionic Update InvestorPlace
10:05AM  DexCom, Inc. breached its 50 day moving average in a Bullish Manner : DXCM-US : September 12, 2017 Capital Cube
08:02AM  See what the IHS Markit Score report has to say about Dexcom Inc. Markit
Sep-11-17 08:05AM  See what the IHS Markit Score report has to say about Dexcom Inc. Markit
Sep-09-17 03:11PM  Fitbit Investors Are Getting Too Excited About This Announcement Motley Fool
Sep-08-17 05:22PM  DexCom Announces Upcoming Conference Presentation Business Wire
07:05AM  Fitbit shares close up 10% on diabetes-monitoring partnership in new smartwatch MarketWatch
Sep-07-17 02:44PM  Fitbit shares jump following a partnership with diabetes-tracking DexCom CNBC -5.19%
12:37PM  Why Fitbit Stock Is Soaring Today Motley Fool
10:03AM  Fitbit shares jump almost 10% on news to work with Dexcom on diabetes product MarketWatch
09:00AM  Fitbit and Dexcom to Develop Continuous Glucose Monitoring (CGM) Experience for People Living with Diabetes Business Wire
Sep-01-17 07:39AM  Why Is DexCom (DXCM) Up 11.6% Since the Last Earnings Report? Zacks
Aug-25-17 06:48PM  DexCom, Inc. Value Analysis (NASDAQ:DXCM) : August 25, 2017 Capital Cube
Aug-21-17 05:00PM  New Study Shows People with Type 2 Diabetes Benefit from Continuous Glucose Monitoring Business Wire
Aug-18-17 08:06AM  See what the IHS Markit Score report has to say about Dexcom Inc. Markit
Aug-17-17 08:33AM  DexCom, Inc. breached its 50 day moving average in a Bullish Manner : DXCM-US : August 17, 2017 Capital Cube
07:20AM  Earnings Review and Free Research Report: DexComs Q2 Top-line Surged 24%; Outshined Forecasts ACCESSWIRE
Aug-15-17 08:05AM  See what the IHS Markit Score report has to say about Dexcom Inc. Markit
Aug-13-17 05:10AM  Edited Transcript of DXCM earnings conference call or presentation 1-Aug-17 8:30pm GMT Thomson Reuters StreetEvents
Aug-11-17 08:06AM  See what the IHS Markit Score report has to say about Dexcom Inc. Markit
Aug-03-17 08:44AM  DexCom (DXCM) in Focus: Stock Moves 6.7% Higher Zacks
Aug-02-17 08:24AM  DexCom (DXCM) Q2 Loss Narrower Than Expected, Revenues Beat Zacks +6.67%
08:00AM  DexCom Announces Upcoming Conference Presentation Business Wire
Aug-01-17 10:05PM  DexCom beats Street 2Q forecasts Associated Press
04:01PM  DexCom, Inc. Reports Second Quarter 2017 Financial Results Business Wire
11:15AM  Investor Network: DexCom, Inc. to Host Earnings Call ACCESSWIRE
Jul-24-17 03:30PM  ETFs with exposure to DexCom, Inc. : July 24, 2017 Capital Cube
Jul-17-17 09:04AM  DexCom, Inc. breached its 50 day moving average in a Bullish Manner : DXCM-US : July 17, 2017 Capital Cube
Jul-14-17 02:03PM  ETFs with exposure to DexCom, Inc. : July 14, 2017 Capital Cube
Jul-07-17 08:00AM  DexCom Announces Upcoming Conference Presentation Business Wire
Jul-05-17 01:28PM  DexCom, Inc. Value Analysis (NASDAQ:DXCM) : July 5, 2017 Capital Cube
Jul-04-17 09:55AM  DexCom, Inc. breached its 50 day moving average in a Bearish Manner : DXCM-US : July 4, 2017 Capital Cube
Jun-20-17 08:30AM  DexCom Schedules Second Quarter 2017 Earnings Release and Conference Call for August 1, 2017 at 4:30 p.m. Eastern Time Business Wire
Jun-09-17 01:27PM  3 Growth Stocks for Ambitious Investors Motley Fool
08:00AM  New Study Shows Adults with Type 1 and Type 2 Diabetes on Multiple Daily Injections (MDI) Benefit from CGM Business Wire
Jun-08-17 08:00AM  Dexcom to Add Ambulatory Glucose Profile (AGP) to Dexcom CLARITY® Business Wire
Jun-07-17 08:58AM  DexCom Shares Rise After FDA Approves G5 Mobile App for Android Devices TheStreet.com
08:05AM  DexCom wins FDA approval for G5 mobile app for android devices MarketWatch
08:00AM  DexCom Announces FDA Approval of G5 Mobile App for Android Devices Business Wire
Jun-06-17 10:04AM  Company News for June 06, 2017 Zacks
08:30AM  Strength Seen in DexCom (DXCM): Stock Adds 5% in Session Zacks
Jun-05-17 02:54PM  DexCom (DXCM) Stock Rallies on Apple Watch Partnership Zacks +5.19%
02:30PM  DexCom Stock Surging on Apple Watch Partnership TheStreet.com
02:08PM  The Apple Watch is about to get a lot more useful with swappable bands to track health symptoms CNBC
01:53PM  Apple Watch to allow glucose data pulling from Dexcom CNBC Videos
01:46PM  DexCom shares jump nearly 4% on Tim Cook's comments on glucose monitors at Apple event MarketWatch
Jun-02-17 07:20AM  DexCom (DXCM) Down 9.6% Since Earnings Report: Can It Rebound? Zacks
May-30-17 08:15AM  Post Earnings Coverage as Charles River Laboratories' Revenue Surged 25.6%, non-GAAP EPS Jumped 32% Accesswire
May-29-17 12:45PM  ETFs with exposure to DexCom, Inc. : May 29, 2017 Capital Cube
May-18-17 01:40PM  ETFs with exposure to DexCom, Inc. : May 18, 2017 Capital Cube
May-17-17 07:17PM  Cramer Remix: Here are the winners after Wednesdays mark... CNBC Videos
May-16-17 09:03AM  Will Wearable Technology Make Us Healthier? Motley Fool
05:18AM  Edited Transcript of DXCM earnings conference call or presentation 2-May-17 8:30pm GMT Thomson Reuters StreetEvents
May-15-17 07:35PM  Some Silicon Valley techies obsessively track their blood sugar -- and they don't have diabetes CNBC
11:42AM  What's Alphabet Got to Do With Healthcare? Motley Fool
08:00AM  DexCom Announces Upcoming Conference Presentation Business Wire
May-08-17 07:57PM  DexCom Prices Offering of $350 Million of 0.75% Convertible Senior Notes Business Wire
07:09AM  DexCom Announces Proposed Offering of $300 Million of Convertible Senior Notes Business Wire
May-05-17 04:05PM  ETFs with exposure to DexCom, Inc. : May 5, 2017 Capital Cube
08:50AM  Edited Transcript of DXCM earnings conference call or presentation 2-May-17 8:30pm GMT Thomson Reuters StreetEvents
May-04-17 10:10AM  DexCom, Inc. :DXCM-US: Earnings Analysis: Q1, 2017 By the Numbers : May 4, 2017 Capital Cube
04:00AM  Dexcom G5® Mobile Continuous Glucose Monitoring (CGM) System now Compatible with Apple Watches in Europe PR Newswire
May-03-17 04:41PM  DexCom, Inc. Value Analysis (NASDAQ:DXCM) : May 3, 2017 Capital Cube -9.48%
12:40PM  Here's Why DexCom Stock Is Tanking Today Motley Fool
08:41AM  DexCom (DXCM) Q1 Loss Narrower than Expected, Revenues Miss Zacks
May-02-17 05:12PM  DexCom reports 1Q loss Associated Press
04:01PM  DexCom, Inc. Reports First Quarter 2017 Financial Results Business Wire
08:10AM  DexCom, Inc. breached its 50 day moving average in a Bullish Manner : DXCM-US : May 2, 2017 Capital Cube
May-01-17 10:17AM  Medical Product Q1 Earnings Due on May 2: BDX, DXCM & More Zacks
Apr-24-17 12:47PM  Sohn Investment Conference: Investing for good CNBC Videos
Apr-19-17 08:00AM  Dexcom Has a Big Ally if Apple Gets Into Its Corner of the Diabetes Market Bloomberg
Apr-14-17 02:30PM  Dexcom adding 500 jobs in Mesa American City Business Journals
DexCom, Inc., a medical device company, together with its subsidiaries, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company offers its systems for ambulatory use by people with diabetes; and for use by healthcare providers in the hospital for the treatment of patients with and without diabetes. Its products include DexCom G4 PLATINUM system for continuous use by adults with diabetes; DexCom G4 PLATINUM with Share, a remote monitoring system; and DexCom G5 Mobile, a CGM system that directly communicates to a patient's mobile and its data can be integrated with DexCom CLARITY, which is a next generation cloud-based reporting software for personalized, easy-to-understand analysis of trends to improve diabetes management. The company also offers sensor augmented insulin pumps. It has a collaboration and license agreement with Verily Life Sciences LLC to develop a series of next-generation CGM products. The company markets its products directly to endocrinologists, physicians, and diabetes educators. The company was founded in 1999 and is headquartered in San Diego, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Pacelli Steven RobertEVP, Strategy & Corp. Dev.Sep 25Sale69.811,450101,21999,326Sep 27 07:49 PM
DOUBLEDAY RICHARDEVP, Chief Commercial OfficerSep 25Sale69.771,635114,08022,150Sep 27 07:49 PM
SAYER KEVIN RPresident & CEOSep 20Sale69.346,000416,044298,826Sep 22 06:13 PM
Balo Andrew KEVP, Reg. Strategy, ClinicalSep 11Sale72.273,244234,44196,813Sep 13 06:23 PM
DOUBLEDAY RICHARDEVP, Chief Commercial OfficerAug 23Sale75.261,635123,05323,785Aug 24 07:31 PM
Pacelli Steven RobertEVP, Strategy & Corp. Dev.Aug 23Sale75.263,987300,045108,087Aug 24 07:31 PM
SAYER KEVIN RPresident & CEOAug 11Sale69.776,000418,637320,680Aug 15 05:52 PM
Balo Andrew KEVP, Reg. Strategy, ClinicalAug 10Sale71.183,244230,92199,989Aug 11 05:54 PM
Pacelli Steven RobertEVP, Strategy & Corp. Dev.Jul 24Sale69.471,450100,725112,074Jul 25 08:55 PM
SAYER KEVIN RPresident & CEOJul 12Sale71.866,000431,174326,680Jul 12 05:33 PM
Balo Andrew KEVP, Reg. Strategy, ClinicalJul 10Sale71.553,200228,972103,233Jul 12 05:32 PM
Pacelli Steven RobertEVP, Strategy & Corp. Dev.Jun 23Sale78.191,450113,378113,524Jun 27 06:55 PM
DOUBLEDAY RICHARDEVP, Chief Commercial OfficerJun 23Sale78.223,187249,27325,420Jun 27 06:56 PM
SAYER KEVIN RPresident & CEOJun 12Sale69.076,000414,411332,680Jun 13 05:26 PM
Balo Andrew KEVP, Clinical and RegulatoryJun 12Sale69.063,200220,989106,433Jun 13 05:27 PM
GREGG TERRANCE HExecutive ChairmanMay 24Option Exercise6.8530,000205,500484,559May 26 04:24 PM
Pacelli Steven RobertEVP, Strategy & Corp. Dev.May 23Sale68.241,45098,949114,974May 25 07:16 PM
DOUBLEDAY RICHARDEVP, Chief Commercial OfficerMay 23Sale68.293,182217,29028,607May 25 07:15 PM
SAYER KEVIN RPresident & CEOMay 17Option Exercise8.793,64932,075347,329May 18 05:46 PM
SAYER KEVIN RPresident & CEOMay 17Sale68.398,649591,525338,680May 18 05:46 PM
Balo Andrew KEVP, Clinical and RegulatoryMay 10Sale71.933,200230,176109,633May 12 06:19 PM
Pacelli Steven RobertEVP, Strategy & Corp. Dev.Apr 24Sale75.891,450110,041117,424Apr 26 07:04 PM
DOUBLEDAY RICHARDEVP, Chief Commercial OfficerApr 24Sale75.783,182241,1316,369Apr 26 07:04 PM
GREGG TERRANCE HExecutive ChairmanApr 20Sale74.1015,0001,111,50040,882Apr 24 06:13 PM
SAYER KEVIN RPresident & CEOApr 17Option Exercise8.7910,00087,900353,680Apr 19 05:20 PM
SAYER KEVIN RPresident & CEOApr 17Sale75.6310,000756,317343,680Apr 19 05:20 PM
Balo Andrew KEVP, Clinical and RegulatoryApr 10Sale78.193,200250,208112,833Apr 12 05:31 PM
DOUBLEDAY RICHARDEVP, Chief Commercial OfficerMar 23Sale76.383,182243,0299,551Mar 24 05:53 PM
Pacelli Steven RobertEVP, Strategy & Corp. Dev.Mar 23Sale76.253,987304,006118,874Mar 24 05:54 PM
ROPER JESSSVP, CFOMar 22Sale75.972,000151,9378,452Mar 24 05:53 PM
SAYER KEVIN RPresident & CEOMar 17Option Exercise8.7910,00087,900353,680Mar 21 06:03 PM
SAYER KEVIN RPresident & CEOMar 17Sale77.8210,000778,158343,680Mar 21 06:03 PM
KAHN BARBARADirectorMar 14Sale77.363,000232,08021,304Mar 16 06:04 PM
Leach Jacob StevenSVP, Research & DevelopmentMar 14Sale77.323,050235,82482,155Mar 15 08:40 PM
VALDES JORGE ACTOMar 13Sale77.7414,4001,119,51410,442Mar 14 07:59 PM
Leach Jacob StevenSVP, Research & DevelopmentMar 13Sale77.977,926617,99185,205Mar 15 08:40 PM
Leach Jacob StevenSVP, Research & DevelopmentMar 10Option Exercise7.637,50057,22593,131Mar 15 08:40 PM
Balo Andrew KEVP, Clinical and RegulatoryMar 10Sale77.713,200248,672129,463Mar 14 07:57 PM
LISTER JOHNGeneral Manager, EMEAMar 09Option Exercise8.853,00026,55096,732Mar 10 08:49 PM
Leach Jacob StevenSVP, Research & DevelopmentMar 09Sale77.4710,341801,07295,592Mar 15 08:40 PM
LISTER JOHNGeneral Manager, EMEAMar 09Sale77.673,000233,00293,732Mar 10 08:49 PM
SKYLER JAY SDirectorMar 06Option Exercise7.3131,890233,11649,136Mar 08 06:28 PM
SKYLER JAY SDirectorMar 06Sale78.1331,8902,491,57217,246Mar 08 06:28 PM
DOUBLEDAY RICHARDEVP, Chief Commercial OfficerFeb 23Sale78.423,182249,53012,733Feb 24 07:52 PM
ROPER JESSSVP, CFOFeb 22Sale78.762,333183,75910,452Feb 24 07:51 PM
SAYER KEVIN RPresident & CEOFeb 17Option Exercise8.7910,00087,900309,391Feb 22 06:14 PM
SAYER KEVIN RPresident & CEOFeb 17Sale81.6210,000816,177299,391Feb 22 06:14 PM
Balo Andrew KEVP, Clinical and RegulatoryFeb 10Option Exercise9.807277,125107,072Feb 14 07:49 PM
Balo Andrew KEVP, Clinical and RegulatoryFeb 10Sale79.303,200253,760103,872Feb 14 07:49 PM
LISTER JOHNGeneral Manager, EMEAFeb 09Option Exercise8.853,00026,55073,598Feb 13 07:19 PM
VALDES JORGE ACTOFeb 09Option Exercise9.807,00068,60079,334Feb 13 07:18 PM
LISTER JOHNGeneral Manager, EMEAFeb 09Sale79.733,000239,20470,598Feb 13 07:19 PM
VALDES JORGE ACTOFeb 09Sale79.767,000558,31672,334Feb 13 07:18 PM
VALDES JORGE ACTOFeb 01Option Exercise9.8013,900136,22086,234Feb 03 07:49 PM
VALDES JORGE ACTOFeb 01Sale80.0013,9001,112,00072,334Feb 03 07:49 PM
Pacelli Steven RobertEVP, Strategy & Corp. Dev.Jan 23Option Exercise7.799,63775,072120,046Jan 25 08:49 PM
DOUBLEDAY RICHARDEVP, Chief Commercial OfficerJan 23Sale79.503,182252,97815,915Jan 25 08:49 PM
Pacelli Steven RobertEVP, Strategy & Corp. Dev.Jan 23Sale79.999,637770,908110,409Jan 25 08:49 PM
ROPER JESSSVP, CFOJan 18Sale85.013,012256,05112,785Jan 20 06:37 PM
SAYER KEVIN RPresident & CEOJan 17Option Exercise8.7910,00087,900309,391Jan 19 08:33 PM
SAYER KEVIN RPresident & CEOJan 17Sale85.9410,000859,362299,391Jan 19 08:33 PM
VALDES JORGE ACTOJan 13Option Exercise8.9726,100234,08082,334Jan 18 07:37 PM
LISTER JOHNGeneral Manager, EMEAJan 13Option Exercise8.8515,000132,75085,598Jan 18 07:38 PM
LISTER JOHNGeneral Manager, EMEAJan 13Sale79.3615,0001,190,40070,598Jan 18 07:38 PM
VALDES JORGE ACTOJan 13Sale80.0026,1002,088,00072,334Jan 18 07:37 PM
Balo Andrew KEVP, Clinical and RegulatoryJan 10Option Exercise9.803,20031,360109,545Jan 12 07:21 PM
Balo Andrew KEVP, Clinical and RegulatoryJan 10Sale62.863,200201,152106,345Jan 12 07:21 PM
VALDES JORGE ACTOJan 09Option Exercise7.3710,90080,29179,334Jan 11 07:31 PM
LISTER JOHNGeneral Manager, EMEAJan 09Option Exercise8.853,00026,55073,598Jan 11 07:33 PM
LISTER JOHNGeneral Manager, EMEAJan 09Sale63.023,000189,04670,598Jan 11 07:33 PM
VALDES JORGE ACTOJan 09Sale63.0210,900686,90572,334Jan 11 07:31 PM
DOUBLEDAY RICHARDEVP, Chief Commercial OfficerDec 23Sale62.173,182197,83119,097Dec 28 08:12 PM
ROPER JESSSVP, CFODec 14Sale64.142,442156,61915,797Dec 16 07:20 PM
VALDES JORGE ACTODec 09Option Exercise7.6010,00076,04376,259Dec 13 04:21 PM
VALDES JORGE ACTODec 09Sale64.8110,000648,07972,334Dec 13 04:21 PM
DOUBLEDAY RICHARDEVP, Chief Commercial OfficerNov 23Sale70.193,182223,35022,279Nov 28 07:29 PM
Pacelli Steven RobertEVP, Strategy & Corp. Dev.Nov 23Sale70.3210,300724,260110,409Nov 28 07:27 PM
LISTER JOHNGeneral Manager, EMEANov 09Sale62.503,417213,56370,598Nov 14 06:31 PM
ROPER JESSSVP, CFOOct 24Sale80.752,471199,54474,215Oct 26 05:08 PM
Pacelli Steven RobertEVP, Strategy & Corp. Dev.Oct 24Sale81.9510,300844,065120,709Oct 26 05:08 PM
DOUBLEDAY RICHARDEVP, Chief Commercial OfficerOct 24Sale81.123,182258,11025,461Oct 26 05:07 PM